Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG Comments to EEOC Concerning Proposed Rule Related to the Genetic Information Nondiscrimination Act (GINA)
-
ACMG Comments to OHRP Concerning Proposed Revisions to the Common Rule
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs
-
Group Sign-on Letter to Congress Urging Modernization of the Clinical Laboratory Improvement Amendments (CLIA)
-
ACMG Comments to EEOC Concerning Regulations Under the Americans with Disabilities Act (ADA)
-
ACMG Comments to FDA Concerning the FDA Draft Guidance on the Framework for Regulatory Oversight of LDTs